Eli Lilly and Company

Eli Lilly and Company, known as Lilly, is a globally leading research-driven biopharmaceutical company headquartered in Indianapolis, Indiana, USA. With a brand heat score of 890/1000, Lilly has established itself as a dominant force in metabolic diseases and oncology treatment worldwide. The company operates across more than 120 countries with approximately 58,000 employees and generated approximately $42 billion in revenue during fiscal year 2025.

Core Business

Lilly's core business centers on the discovery, development, manufacturing, and commercialization of innovative medicines across several high-impact therapeutic areas. The company's flagship franchise in metabolic diseases is anchored by its GLP-1 receptor agonist portfolio, led by Tirzepatide (Mounjaro® and Zepbound®) and Dulaglutide (Trulicity®), which have achieved blockbuster status in both diabetes and obesity treatment. Lilly also maintains a comprehensive insulin portfolio featuring various insulin analogs, serving the substantial global population requiring glycemic management. In fiscal year 2025, the metabolic disease segment, driven primarily by GLP-1 products, represented approximately 70% of total company revenue, demonstrating the transformative impact of these differentiated therapeutic solutions.

In oncology, Lilly has built a significant presence through targeted therapies and immuno-oncology agents. The company's cancer treatment portfolio includes checkpoint inhibitors and multiple targeted drug candidates addressing various tumor types. The oncology business contributed approximately 15% of total revenues in fiscal year 2025, growing at a steady 12.5% year-over-year. Additionally, Lilly maintains growing positions in rare diseases and growth disorders through its human growth hormone products, as well as emerging capabilities in immunology with innovative treatments for autoimmune and inflammatory conditions. The company maintains one of the most robust pipelines in the pharmaceutical industry, with annual R&D investment exceeding $8.4 billion, representing approximately 20% of revenue, supporting advancement across all therapeutic areas.

Global Presence

Lilly maintains an extensive global operational footprint spanning 120+ countries across North America, Europe, Asia-Pacific, Latin America, and emerging markets. The company operates 15 manufacturing facilities strategically distributed across major pharmaceutical markets, 10 R&D centers housing more than 10,000 research personnel, and 8 logistics hubs enabling efficient global supply chain management. With approximately 58,000 employees worldwide, of which 17% are dedicated to research and development, Lilly has built a deeply integrated global network capable of addressing diverse patient populations.

The United States remains Lilly's largest and most strategic market, accounting for approximately 60% of global revenue, driven by strong uptake of GLP-1 medications and innovative product launches. Europe contributes approximately 20% of revenues across more than 30 countries, including key markets such as Germany, France, and the United Kingdom. The Asia-Pacific region, led by China, Japan, and Australia, represents a high-growth market with 35.5% year-over-year growth, now accounting for approximately 15% of total revenue. Remaining markets including Latin America, Africa, and the Middle East contribute the remaining 5%, representing emerging opportunities for expansion.

Key Strengths

Lilly's competitive positioning is defined by several interconnected advantages that reinforce its market leadership. The company's unparalleled strength in GLP-1 science has established it as the global leader in metabolic disease treatment, with a diversified portfolio spanning diabetes, obesity, and future pipeline candidates including oral formulations. Lilly's commitment to R&D intensity, investing over $8 billion annually, ensures a sustained flow of innovative products and positions it at the forefront of next-generation therapeutic platforms including gene therapy and novel immunological approaches. The company's vertically integrated manufacturing network, compliant with global cGMP standards, provides supply chain resilience and quality assurance that supports brand trust among healthcare providers and patients worldwide.